<DOC>
	<DOC>NCT01422187</DOC>
	<brief_summary>This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (â‰¥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.</brief_summary>
	<brief_title>A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Successfully completed Protocol PB06001 and enrolled in Protocol PB06003 The subject signs an informed consent Currently taking another investigational drug for any condition. Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>enzyme replacement therapy</keyword>
</DOC>